RxSight, Inc. Announces Chief Financial Officer Transition

Rhea-AI Summary

RxSight (NASDAQ:RXST) announced that Shelley Thunen, its Chief Financial Officer, is transitioning from the CFO role and will remain with the company until the sooner of her successor's appointment or January 31, 2026. Ms. Thunen has agreed to support RxSight as a consultant after the transition.

The release highlights Ms. Thunen's nearly decade of service, her role in the company's 2021 IPO, and operational achievements under her finance leadership, including more than 1,100 light-adjustable intraocular devices (LDDs) in the field and over 250,000 procedures performed. The CEO and board expressed gratitude for her contributions.

Positive

• CFO will remain until successor or Jan 31, 2026
• CFO agreed to continue as a consultant after transition
• Nearly a decade of CFO tenure with company
• Finance leadership through 2021 IPO
• 1,100+ LDDs in field and 250,000+ procedures

Negative

• Current CFO role will be vacated by Jan 31, 2026, creating near-term leadership change

Key Figures

Installed LDDs more than 1,100 devices Light Delivery Devices in the field cited in CFO transition release

Procedures performed over a quarter million Procedures performed with company technology since inception

CFO transition date January 31, 2026 Latest date through which current CFO remains in role

IPO year 2021 Year of RxSight initial public offering mentioned in article

Market Reality Check

$10.38 Last Close

Volume Volume 574,398 vs 20‑day average 885,636 (relative volume 0.65) indicates lighter trading ahead of this announcement. low

Technical Shares at $12.23 were trading below the 200‑day MA of $12.45, with the stock already 68.35% under its 52‑week high.

Peers on Argus

RXST was down 2.27% while key device peers were mostly flat to up, including BFLY up 4.11%, SENS up 2.11%, and CBLL up 0.43%, suggesting stock‑specific pressures rather than a sector‑wide move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 20	Conference participation	Positive	-5.8%	Piper Sandler healthcare conference presentation and webcast details.
Nov 05	Earnings results	Negative	-7.3%	Q3 2025 revenue decline, lower LDD sales, updated guidance.
Oct 22	Earnings call notice	Neutral	-1.2%	Announcement of date and access details for Q3 2025 call.
Oct 16	Product education	Positive	-2.8%	Live Learning Sessions on Light Adjustable Lens at AAO 2025.
Aug 25	Conference participation	Positive	-1.3%	Planned presentation at Morgan Stanley Healthcare Conference.

Pattern Detected

Recent RXST headlines, including conferences and product visibility events, often coincided with negative price reactions, even when the news itself appeared neutral to positive. Only the Q3 2025 earnings event showed price action directionally aligned with a negative fundamental update.

Recent Company History

Over the last six months, RxSight has focused on investor outreach and operational updates, presenting at the Morgan Stanley and Piper Sandler healthcare conferences and highlighting its Light Adjustable Lens platform at AAO 2025. Financially, Q3 2025 results on Nov 5 showed lower revenue and a wider loss, with guidance narrowed but margins improved. Notably, each of these prior announcements, including conference participation and earnings, was followed by a negative 24h price reaction, framing today’s CFO transition within a backdrop of recent share‑price weakness.

Market Pulse Summary

This announcement details an orderly CFO transition, with the incumbent finance leader remaining through the earlier of a successor’s appointment or January 31, 2026 and then supporting the company as a consultant. The release underscores RxSight’s commercial base of more than 1,100 Light Delivery Devices and over a quarter million procedures, and references its 2021 IPO. In context of recent earnings pressure and repeated conference outreach, investors may watch for updates on financial strategy and leadership succession progress.

Key Terms

ophthalmic medical

"RxSight, Inc., an ophthalmic medical device company dedicated..."

Relating to the eye and its care, including medicines, drops, diagnostic tools and surgical devices used to prevent, diagnose or treat eye conditions. Investors care because ophthalmic products form a distinct market with specialized safety approvals, manufacturing needs and payer coverage, so success or failure in this area can drive steady revenue or costly setbacks—think of it as a niche, high‑safety consumer product line for vision health.

cataract surgery medical

"customized vision to patients following cataract surgery, today announced..."

A surgical procedure that removes a cloudy natural lens in the eye and usually replaces it with a clear artificial lens, restoring vision much like cleaning or replacing a fogged camera lens to get a sharp picture again. It matters to investors because the procedure drives demand for medical devices, implants, surgical equipment and related services, so changes in procedure volume, technology, pricing or reimbursement can directly affect revenue and growth prospects for healthcare companies.

initial public offering financial

"including our initial public offering in 2021, and positioned RxSight..."

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

AI-generated analysis. Not financial advice.

ALISO VIEJO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that Shelley Thunen, the Company’s Chief Financial Officer, is transitioning from her role. Ms. Thunen will remain with the Company until the sooner of the appointment of her successor or January 31, 2026. Ms. Thunen has agreed to support the Company as a consultant subsequent to the transition.

“Shelley has been a key and trusted partner throughout some of the most important years in RxSight’s development,” said Ron Kurtz, Chief Executive Officer and President of RxSight. “Shelley developed and executed on our financial strategy, and over nearly a decade, her leadership and unwavering commitment helped guide RxSight from a pre-commerical company to one with more than 1,100 LDDs in the field and over a quarter million procedures performed. She has shaped the foundation we rely on today, and we are truly grateful for everything she has done for our patients, our customers, and everyone at RxSight.”

“Shelley has had a profound impact on RxSight,” said Andy Corley, Chairman of the Board. “Her judgment, integrity, and dedication helped guide the Company through pivotal events, including our initial public offering in 2021, and positioned RxSight for the opportunities ahead. The Board is sincerely appreciative of her service and the lasting mark she leaves on the organization.”

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight^® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens^® (LAL^®/LAL+^®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com

Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com

FAQ

When will Shelley Thunen leave the CFO role at RxSight (RXST)?

Ms. Thunen will remain CFO until the sooner of the appointment of her successor or January 31, 2026.

Will Shelley Thunen continue working with RxSight after stepping down as CFO?

Yes. Ms. Thunen has agreed to support RxSight as a consultant after the transition.

What operational milestones did RxSight cite under CFO Shelley Thunen's tenure?

The company cited > 1,100 LDDs in the field and > 250,000 procedures performed during her tenure.

Did Shelley Thunen serve through RxSight's IPO and when was it?

Yes. The company credited her guidance through its initial public offering in 2021.

How might RxSight's CFO transition affect operations in the near term for RXST shareholders?

The announcement creates a defined transition window through Jan 31, 2026 and notes continuity via a consulting arrangement for the outgoing CFO.